Wells Fargo Downgrades Soleno Therapeutics to Equal-Weight, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 89.9%

Neg 89.9% Neu 0% Pos 0%

Wells Fargo analyst Derek Archila downgrades Soleno Therapeutics (NASDAQ:SLNO) from Overweight to Equal-Weight and lowers the price target from $110 to $53.